PRESS RELEASE published on 01/26/2024 at 14:00, 10 months 26 days ago Optimind Pharma - Debenture Conversion Optimind Pharma Corp. (CSE:OMND) announces agreement to convert $303,750 convertible debentures at $0.025/share, potentially issuing 23,333,500 shares. Optimind focuses on psychedelic therapies for mental health. Convertible Debentures Optimind Pharma Corp. CSE:OMND Psychedelic Therapies Mental Health
Published on 12/21/2024 at 01:30, 17 hours 17 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 17 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 42 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 19 hours 17 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 17 hours 55 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 1 minute ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 36 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 23 hours 50 minutes ago CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/21/2024 at 12:17, 6 hours 29 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 17:55, 1 day ago Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 4 hours ago Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago Share capital decrease by way of treasury shares cancellation
